CR7921A - Formulaciones farmaceuticas liquidas de palonosetron - Google Patents

Formulaciones farmaceuticas liquidas de palonosetron

Info

Publication number
CR7921A
CR7921A CR7921A CR7921A CR7921A CR 7921 A CR7921 A CR 7921A CR 7921 A CR7921 A CR 7921A CR 7921 A CR7921 A CR 7921A CR 7921 A CR7921 A CR 7921A
Authority
CR
Costa Rica
Prior art keywords
palonosetron
pharmaceutical formulations
liquid pharmaceutical
formulations
liqueid
Prior art date
Application number
CR7921A
Other languages
English (en)
Inventor
Braglia Enrico
Bonadeo Daniele
Cannella Roberta
Calderari Giorgio
Braglia Riccardo
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CR7921A publication Critical patent/CR7921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Abstract

Formulaciones liqueidas de palonosetron de almacenamiento estable para reducir una emesis inducida por quimioterapia y raditerapia con palonosetron. las formulaciones son de particular utilidad en la preparacion de medicamentos liquidos intravenosos y orales.
CR7921A 2003-01-30 2005-07-22 Formulaciones farmaceuticas liquidas de palonosetron CR7921A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30

Publications (1)

Publication Number Publication Date
CR7921A true CR7921A (es) 2006-02-07

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7921A CR7921A (es) 2003-01-30 2005-07-22 Formulaciones farmaceuticas liquidas de palonosetron

Country Status (41)

Country Link
US (9) US7947724B2 (es)
EP (2) EP2008659A1 (es)
JP (2) JP5461763B2 (es)
KR (1) KR101113084B1 (es)
CN (2) CN102813621A (es)
AP (1) AP2110A (es)
AR (1) AR042977A1 (es)
AT (1) ATE410167T1 (es)
AU (1) AU2004208505C1 (es)
BR (1) BRPI0407121B8 (es)
CA (5) CA2573194A1 (es)
CR (1) CR7921A (es)
CY (1) CY1108660T1 (es)
DE (1) DE602004016967D1 (es)
DK (1) DK1601359T3 (es)
EA (1) EA014066B1 (es)
EC (1) ECSP055938A (es)
ES (1) ES2315635T3 (es)
GE (1) GEP20084445B (es)
HK (1) HK1076401A1 (es)
HR (1) HRP20050676B1 (es)
IL (1) IL169859A (es)
IS (1) IS7984A (es)
JO (1) JO2735B1 (es)
MA (1) MA27710A1 (es)
MX (1) MXPA05008028A (es)
MY (1) MY144036A (es)
NO (1) NO329500B1 (es)
NZ (1) NZ541533A (es)
PA (1) PA8594801A1 (es)
PE (1) PE20050066A1 (es)
PL (1) PL378398A1 (es)
PT (1) PT1601359E (es)
RS (1) RS20050578A (es)
SI (1) SI1601359T1 (es)
TN (1) TNSN05180A1 (es)
TW (1) TWI342212B (es)
UA (1) UA90449C2 (es)
UY (1) UY28175A1 (es)
WO (1) WO2004067005A1 (es)
ZA (1) ZA200506917B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100143461A1 (en) 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN102781939A (zh) 2009-11-13 2012-11-14 赫尔辛医疗股份公司 帕洛诺司琼代谢物
CN104856998A (zh) 2009-11-18 2015-08-26 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
EP3087987A4 (en) * 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
CA3025837C (en) * 2016-06-06 2024-02-13 Helsinn Healthcare Sa Physiologically balanced injectable formulations of fosnetupitant
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
HU218654B (hu) * 1989-11-28 2000-10-28 Syntex (U.S.A.) Inc. Triciklusos vegyületek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és eljárás előállításukra
ES2149305T3 (es) 1991-05-03 2000-11-01 Searle & Co Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
WO2000024375A1 (en) * 1998-10-27 2000-05-04 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
CN1525856A (zh) 2001-05-11 2004-09-01 三菱制药株式会社 含吡唑啉酮衍生物的稳定的高浓度注射剂
WO2003100091A1 (en) 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ES2285407T3 (es) 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
MA27710A1 (fr) 2006-01-02
HRP20050676B1 (hr) 2013-02-28
NO329500B1 (no) 2010-11-01
US9457020B2 (en) 2016-10-04
IL169859A (en) 2014-11-30
US7960424B2 (en) 2011-06-14
DK1601359T3 (da) 2009-01-05
GEP20084445B (en) 2008-08-10
AU2004208505B2 (en) 2009-09-03
CA2573241A1 (en) 2004-08-12
UA90449C2 (ru) 2010-05-11
IS7984A (is) 2005-08-15
ES2315635T3 (es) 2009-04-01
JP5461763B2 (ja) 2014-04-02
CY1108660T1 (el) 2014-04-09
EP1601359B1 (en) 2008-10-08
JO2735B1 (en) 2013-09-15
JP2006516583A (ja) 2006-07-06
AU2004208505C1 (en) 2015-10-01
PT1601359E (pt) 2008-11-03
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
BRPI0407121A (pt) 2006-01-10
ZA200506917B (en) 2006-08-30
JP5551658B2 (ja) 2014-07-16
BRPI0407121B8 (pt) 2021-06-29
JP2011236242A (ja) 2011-11-24
KR20050104363A (ko) 2005-11-02
US20140039000A1 (en) 2014-02-06
EA014066B1 (ru) 2010-08-30
US20060167073A1 (en) 2006-07-27
US20130267553A1 (en) 2013-10-10
PL378398A1 (pl) 2006-04-03
US20060069114A1 (en) 2006-03-30
UY28175A1 (es) 2004-09-30
TWI342212B (en) 2011-05-21
BRPI0407121B1 (pt) 2018-07-17
CA2573363A1 (en) 2004-08-12
US9308266B2 (en) 2016-04-12
AU2004208505A2 (en) 2004-08-12
KR101113084B1 (ko) 2012-02-15
US20060167071A1 (en) 2006-07-27
PA8594801A1 (es) 2004-09-16
ATE410167T1 (de) 2008-10-15
AR042977A1 (es) 2005-07-13
HRP20050676A2 (en) 2005-10-31
TNSN05180A1 (en) 2007-06-11
US7947725B2 (en) 2011-05-24
ECSP055938A (es) 2006-03-01
TW200418517A (en) 2004-10-01
CN1758911A (zh) 2006-04-12
PE20050066A1 (es) 2005-04-20
CA2514224A1 (en) 2004-08-12
AP2005003382A0 (en) 2005-09-30
EP2008659A1 (en) 2008-12-31
AU2004208505A1 (en) 2004-08-12
NZ541533A (en) 2008-12-24
MXPA05008028A (es) 2006-01-27
DE602004016967D1 (de) 2008-11-20
US8518981B2 (en) 2013-08-27
US20160000773A1 (en) 2016-01-07
SI1601359T1 (sl) 2009-04-30
EA200501203A1 (ru) 2006-06-30
AP2110A (en) 2010-03-01
HK1076401A1 (en) 2006-01-20
EP1601359A1 (en) 2005-12-07
US8598218B2 (en) 2013-12-03
MY144036A (en) 2011-07-29
US20110192493A1 (en) 2011-08-11
US20160317440A1 (en) 2016-11-03
CN102813621A (zh) 2012-12-12
US20140097114A1 (en) 2014-04-10
NO20053987L (no) 2005-08-26
US7947724B2 (en) 2011-05-24
CA2573228A1 (en) 2004-08-12
WO2004067005A1 (en) 2004-08-12
RS20050578A (en) 2007-09-21

Similar Documents

Publication Publication Date Title
CR7921A (es) Formulaciones farmaceuticas liquidas de palonosetron
ITRM20030210A1 (it) Protesi da impiegarsi nella terapia chirurgica del prolasso
AR047540A1 (es) Particulados
NO20053959D0 (no) Medikament omfattende hoy-aktiv langtidsvarende beta-2-abonist i kombinasjon med andre aktive bestanddeler
MY157772A (en) Antibody formulation
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
AR034371A1 (es) Composiciones farmaceuticas
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
IL173369A (en) Combined pharmaceutical preparation containing g - csf and p1gf effective in stimulating mobilization of peripheral blood progenitor cells
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
EA200702496A1 (ru) Местная композиция, содержащая желатин
AR065068A1 (es) Composicion farmaceutica que comprende tramadol y ketoprofeno en asociacion
CY1108785T1 (el) Σταθερη φαρμακευτικη γελη diclofenac na
DE602004014964D1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
DE602004022515D1 (de) Fenofibrate tablett und verfahren zur herstellung
PL381799A1 (pl) Kompozycja farmaceutyczna zawierająca trwały i klarowny roztwór leku przeciwzapalnego w miękkiej kapsułce żelatynowej i sposób jej wytwarzania
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
ITFO20020011A0 (it) Strumento di cannula vaginale atto ad eseguire irrigazioni vaginali con successiva somministrazione in vagina di principi attivi in formulaz
PE20141530A1 (es) Composicion farmaceutica para uso en inflamacion y dolor
ATE456573T1 (de) Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen